InMed Pharmaceuticals Inc. Form 8-K Filing

This Form 8-K filing by InMed Pharmaceuticals Inc. reports on the company's actions regarding its At The Market Offering Agreement. On April 3, 2026, the company filed a prospectus supplement and related prospectus concerning the sale of its common shares. This action was taken in accordance with the terms of the Sales Agreement with H.C. Wainwright & Co., LLC, and under the company's shelf registration statement on Form S-3. The filing includes exhibits such as a legal opinion from Norton Rose Fulbright Canada LLP regarding the legality of the common shares to be issued, and their consent. The company is identified as an emerging growth company.